DNLI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Denali Therapeutics Inc (DNLI) is not a strong buy for a beginner investor with a long-term horizon at this moment. The stock lacks immediate positive trading signals, has insider selling activity, and shows weak financial performance. While analysts maintain a generally positive outlook with increased price targets, the technical indicators and options data suggest a cautious approach.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 31.86, close to oversold territory but not providing a clear signal. Moving averages are converging, showing no strong trend. Key support is at 19.357, and resistance is at 21.567.
Analysts have increased price targets recently, with BTIG raising the target to $36 and Morgan Stanley to $40, maintaining Buy and Overweight ratings. The company has a strong FDA relationship and expertise in complex drug approvals.
Insiders are selling heavily, with an 844.50% increase in selling activity over the last month. The MACD and technical indicators suggest bearish momentum. Financial performance remains weak, with negative net income and EPS, and no revenue growth.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved slightly YoY but remains negative at -$128.5M. EPS also improved but is still negative at -0.73. Gross margin remains at 0%.
Analysts are generally positive, with multiple Buy and Overweight ratings. Price targets range from $25 to $40, indicating potential upside. Wolfe Research initiated coverage with a neutral Peer Perform rating.
